Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2013 | 1 |
2016 | 1 |
2017 | 2 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
IUBMB Life. 2023 Jan;75(1):40-54. doi: 10.1002/iub.2619. Epub 2022 May 2.
IUBMB Life. 2023.
PMID: 35499745
Free PMC article.
Review.
Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
Nesbitt H, Byrne NM, Williams SN, Ming L, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ.
Nesbitt H, et al.
Clin Cancer Res. 2017 Apr 1;23(7):1797-1808. doi: 10.1158/1078-0432.CCR-16-1361. Epub 2016 Oct 3.
Clin Cancer Res. 2017.
PMID: 27697998
Item in Clipboard
The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
Nesbitt H, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ.
Nesbitt H, et al.
Prostate. 2017 Nov;77(15):1539-1547. doi: 10.1002/pros.23434. Epub 2017 Sep 24.
Prostate. 2017.
PMID: 28944496
Free article.
Item in Clipboard
Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.
Ming L, Byrne NM, Camac SN, Mitchell CA, Ward C, Waugh DJ, McKeown SR, Worthington J.
Ming L, et al.
Int J Cancer. 2013 Mar 15;132(6):1323-32. doi: 10.1002/ijc.27796. Epub 2012 Nov 23.
Int J Cancer. 2013.
PMID: 22915157
Free article.
Item in Clipboard
Cite
Cite